Celgene’s investigational and second-generation CAR T-cell therapy bb2121 is showing real promise in treating advanced multiple myeloma patients, those with relapsed or refractory disease, updated…
Screening people with a family history of a multiple myeloma precursor would significantly reduce the chance that a person would develop and die of the cancer, a…
The European Commission has extended Xgeva‘s (denosumab) approval for the prevention of bone lesions in multiple myeloma patients, Amgen, the medicine’s maker, announced. The…
The combination of Revlimid (lenalidomide) and dexamethasone for the treatment of relapsed or refractory multiple myeloma showed similar benefits in routine clinical practice as it did…
Scientists have developed a new test that shortens the time it takes to assess the success of bone marrow transplants — to a few days…
Janssen Pharmaceuticals has requested the U.S. Food and Drug Administration (FDA) add a new indication for Darzalex (daratumumab) in combination with other therapies…
Patients with relapsed and refractory multiple myeloma lived roughly 3.6 months longer without their disease worsening when they received a once-weekly dose of…
Adding Venclexta (venetoclax) to Velcade (bortezomib) and dexamethasone has shown promising effectiveness and an acceptable safety profile in multiple myeloma patients who progressed during or…
Multiple myeloma patients older than 65 years benefit as much as younger patients from autologous stem cell transplant (ASCT), according to a recent retrospective study.